| Thursday, October 15th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:45-09:00 | Welcome Coffee | ||
| 09:00-12:00 | IACH 1: Workshop | ||
| 12:00-12:30 | Lunch Break | ||
| 12:30-13:00 | IACH 2: Awards Session | ||
| 13:00-14:15 | Transplant 1: Advances in Allogeneic Transplantation | 13:00-14:15 | COMydAL 1: MDS I |
| Moderators: Arnon Nagler, Israel; TBA | Moderators: Matteo Della Porta, Italy; Amy DeZern, USA | ||
| 13:00-13:15 | Conditioning regimen: Maud D’Aveni, France |
13:00-13:15 | A new MDS classification ahead? Robert Hasserjian, USA |
| 13:15-13:30 | Revisited TCI: Alexandros Spyridonidis, Greece |
13:15-13:30 | AI in diagnosis and prognostication of MDS and CMML: Matteo Della Porta, Italy |
| 13:30-13:45 | Graft manipulation and Tregs: TBA |
13:30-13:45 | Is there a border between AA and hMDS? Amy DeZern, USA |
| 13:45-14:00 | Novel combination for GVHD prophylaxis: Annalisa Ruggeri, Italy |
13:45-14:00 | Germline predisposition in MDS, diagnosis and impact on therapy: Marie Sebert, France |
| 14:00-14:15 | Panel discussion: All session faculty | 14:00-14:15 | Panel discussion: All session faculty |
| 14:15-15:30 | Transplant 2: HCT/CT in Malignancies | 14:15-15:30 | COMydAL 2: MDS II |
| Moderators: Eolia Brissot, France; TBA | Moderators: Lionel Adès, France; Valeria Santini, Italy | ||
| 14:15-14:30 | Should we transplant TP53 mutated AML? Xavier Poiré, Belgium |
14:15-14:30 | Transplant for MDS in 2026? David Valcárcel, Spain |
| 14:30-14:45 | CAR-T cells or alloHCT for very high-risk B-ALL in first line: He Huang, China |
14:30-14:45 | Diagnosis and treatment of VEXAS and MDS: Jérome Hadjadj, France |
| 14:45-15:00 | T-ALL: TBA |
14:45-15:00 | Therapy of HR MDS: are target drugs the onlyl hope? Lionel Adès, France |
| 15:00-15:15 | State-of-the-art CD19 CAR-T cell therapy in DLBCL and future directions: TBA |
15:00-15:15 | Navigating the treatment of LR-MDS: TBA |
| 15:15-15:30 | Panel discussion: All session faculty | 15:15-15:30 | Panel discussion: All session faculty |
| 15:30-16:45 | Industry Symposium | 15:30-16:45 | Industry Symposium |
| 16:45-17:00 | Coffee Break | ||
| 17:00-18:15 | Transplant 3: HCT/CT in Non-Malignant Disease | 17:00-18:15 | COMydAL 3: CMML, MDS/MPN and others |
| Moderators: TBA | Moderators: Francesco Onida, Italy; Valeria Santini, Italy | ||
| 17:00-17:15 | AlloHCT for sickle cell disease? TBA |
17:00-17:15 | New directions in management of TP53 mutated myeloid neoplasms: Maximilian Stahl, USA |
| 17:15-17:30 | Gene therapy for sickle cell disease? TBA |
17:15-17:30 | Evolving use of oral HMAs in myeloid malignancies: Daniel Wiseman, UK |
| 17:30-17:45 | CAR-T cells in autoimmune disease: Dimitrios Mougiakakos, Germany |
17:30-17:45 | Recommendation transplantation in CMML and MDS/MPN: Francesco Onida, Italy |
| 17:45-18:00 | Gene transfer vs gene editing: efficacy and safety issue: TBA |
17:45-18:00 | Biology and treatment of CMML: Mrinal Patnaik, USA |
| 18:00-18:15 | Panel discussion: All session faculty | 18:00-18:15 | Panel discussion: All session faculty |
IACH track
COMydAL track
COLYM track
MPNCo&D track
Transplant track
| Friday, October 16th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:30-09:45 | Transplant 4: Complications | 08:30-09:45 | COMydAL 4: AML I |
| Moderators: Bipin Savani, USA;TBA | Moderators: Tamara Vasilj, Croatia; Amer Zeidan, USA | ||
| 08:30-08:45 | Endothelial dysfunction: TMA? TBA |
08:30-08:45 | MyeloMatch and pivotal AML studies to watch for in the next 3 years: Selina Luger, USA |
| 08:45-09:00 | Nutrition and frailty scale: María Queralt Salas, Spain |
08:45-09:00 | An update on FLT3 inhibitors use in AML: TBA |
| 09:00-09:15 | Antibiotic stewardship in alloHCT: TBA |
09:00-09:15 | An update on IDH inhibitors use in AML: Stéphane De Botton, France |
| 09:15-09:30 | CNS complications in HCT and CAR-T? Zinaida Perić, Croatia |
09:15-09:30 | An update on menin inhibitors use in AML: Amer Zeidan, USA |
| 09:30-09:45 | Panel discussion: All session faculty | 09:30-09:45 | Panel discussion: All session faculty |
| 09:45-10:00 | Coffee Break | ||
| 10:00-11:15 | Transplant 5: Post HCT Management | 10:00-11:15 | COMydAL 5: AML II |
| Moderators: Anne Huynh, France; TBA | Moderators: Sanam Loghavi, USA; Amer Zeidan, USA | ||
| 10:00-10:15 | Management of MRD in pre and post alloHCT strategies in AML: Jaime Sanz Caballer, Spain |
10:00-10:15 | How should TP53 mutated myeloid neoplasms be classified? Coleman Lindsley, USA |
| 10:15-10:30 | Maintenance in AML: Eolia Brissot, France |
10:15-10:30 | Updates on clinical use of MRD for clinical management of AML: Christoph Röllig, Germany |
| 10:30-10:45 | DLI: Raynier Devillier, France |
10:30-10:45 | Learnings from HARMONY about genetics determinants of outcomes in AML: Lars Bullinger, Germany |
| 10:45-11:00 | Post HCT rehabilitation: Didier Blaise, France |
10:45-11:00 | Harmonization efforts of classifications for AML and MDS: Sanam Loghavi, USA |
| 11:00-11:15 | Panel disucssion: All session faculty | 11:00-11:15 | Panel disucssion: All session faculty |
| 11:15-12:30 | Industry Symposium | 11:15-12:30 | Industry Symposium |
| 12:30-13:00 | Lunch Break | ||
| 13:00-14:15 | COLYM 1: From Biology to Bedside: What Will Really Change Practice? | 13:00-13:05 | Opening: Claire Harrison, UK; Ruben Mesa, USA; Naveen Pemmaraju, USA |
| 13:05-14:15 | MPNCo&D 1: Redefining disease and risk: are we stratifying patients correctly? | ||
| Moderators: TBA | Moderators: Florian Heidel, Germany; Francesca Palandri, Italy | ||
| 13:00-13:05 | Case report: TBA |
13:05-13:20 | Patient perspective on MPN priorities for 2026 and beyond: Werner Zinkland, Germany |
| 13:05-13:15 | Discussion | 13:20-13:35 | Molecular risk models vs clinical judgement: are mutations driving overtreatment? Should we use them more in ET and PV: Jean-Jacques Kiladjian, France |
| 13:15-13:30 | Molecular subtyping and functional genomics: what is ready for routine care? Miguel Angel Piris, Spain |
13:35-13:50 | Clonal hematopoiesis vs early MPN: when does ‘watch and wait’ become unsafe? Adam Mead, UK |
| 13:30-13:45 | ctDNA as a decision-making tool: hype, hope, or hard evidence? Sven Borchmann, Germany |
13:50-14:05 | Symptoms, spleen, survival: which outcome should drive first-line therapy choices in MF? Claire Harrison, UK |
| 13:45-14:00 | Emerging biomarkers for response prediction to novel agents: Brian Hill, USA |
14:05-14:15 | Panel discussion: All session faculty |
| 14:00-14:15 | Panel discussion: All session faculty | ||
| 14:15-15:30 | Industry Symposium | 14:15-15:30 | Industry Symposium |
| 15:30-16:45 | COLYM 2: Redefining Frontline Therapy: Risk, Response, and Reality | 15:30-16:45 | MPNCo&D 2: Anemia in myelofibrosis: mechanism-driven therapy or trial-and-error? |
| Moderators: TBA | Moderators: Adam Mead, UK; David Ross, Australia | ||
| 15:30-15:35 | Case report: TBA |
15:30-15:45 | What causes anemia in MF — cytokines, hepcidin, marrow failure, or treatment effect? David Ross, Australia |
| 15:35-15:45 | Discussion | 15:45-16:00 | ESAs, danazol, steroids: obsolete, underused, or still foundational? Susanne Isfort, Germany |
| 15:45-16:00 | Biology-driven frontline strategies in aggressive B-cell lymphomas: Andrew Davies, UK | 16:00-16:15 | Novel agents targeting anemia pathways in MF: Searching for the Holy Grail: Ruben Mesa, USA |
| 16:00-16:15 | Frontline therapy in high-risk subgroups: elderly fit patients with LBCL: Farrukh Awan, USA |
16:15-16:35 | Anemia as a prognostic marker vs a treatment-limiting toxicity: should it dictate therapy choice? Yes: Juan Carlos Hernandes-Boluda, Spain No: Francesca Palandri, Italy |
| 16:15-16:30 | Managing primary refractory and early relapsed aggressive B-cell lymphomas: optimizing salvage and bridging strategies: Rémy Duléry, USA |
16:35-16:45 | Panel discussion: All session faculty |
| 16:30-16:45 | Panel discussion: All session faculty | ||
| 16:45-17:00 | Coffee Break | ||
| 17:00-18:15 | IACH 3 | ||
| Saturday, October 17th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:30-09:45 | COLYM 3: Sequencing in Relapsed Lymphoma: Making Sense of Too Many Options | 08:30-09:45 | MPNCo&D 3: Next-generation targeted therapies: beyond JAK inhibition in MF |
| Moderators: Mohamed Kharfan-Dabaja, USA; TBA | Moderators: Susanne Isfort, Germany; Andreas Reiter, Germany | ||
| 08:30-08:35 | Case report: TBA | 08:30-08:45 | Selective pathway targeting (e.g. hepcidin, ACVR1, BCL-2 family, Xpo1, MDM2): real differentiation or incremental gains? Jennifer O’Sullivan, UK |
| 08:35-08:45 | Discussion | ||
| 08:45-09:00 | Bispecific antibodies vs cellular therapies in FL: how to choose in real-life practice: Julio Chavez, USA |
08:45-09:00 | Early signals from novel agents targeting CALR in MF: how should clinicians interpret phase 1-2 data? Bethan Psaila, UK |
| 09:00-09:15 | Treatment sequencing in relapsed / refractory MZL: what do we do next? Côme Bommier, France |
09:00-09:15 | Early data on novel JAK inhibitors: molecular markers, phenotype, or treatment history? John Mascarenhas, USA |
| 09:15-09:30 | Treatment sequencing in relapsed / refractory MCL: what do we do next? Carlo Visco, Italy |
09:15-09:35 | Combination strategies for upfront management: all patients INT-1 or above with splenomegaly and symptoms should receive combination therapy if trials are positive Yes: Francesco Passamonti, Italy No: Florian Heidel, Germany |
| 09:30-09:45 | Panel discussion: All session faculty | 09:35-09:45 | Panel discussion: All session faculty |
| 09:45-10:00 | Coffee Break | ||
| 10:00-11:15 | COLYM 4: Hodgkin Lymphoma: Optimizing Therapy Across Risk Groups | 10:00-11:15 | MPNCo&D 4: Transplant, disease evolution, and overlap biology |
| Moderators: TBA | Moderators: Anna Godfrey, UK; Juan Carlos Hernandes-Boluda, Spain | ||
| 10:00-10:05 | Case report: TBA | 10:00-10:15 | Who should be referred for transplant today — and who is being missed? TBA |
| 10:05-10:15 | Discussion | ||
| 10:15-10:30 | Frontline therapy in advanced-stage classical Hodgkin lymphoma: balancing efficacy and toxicity: TBA |
10:15-10:30 | Timing allo-HSCT for atypical MPN: earlier, later, or never? Nicola Polverelli, Italy |
| 10:30-10:45 | PET-adapted and response-adapted strategies: how low can we go? TBA |
10:30-10:45 | Overlap syndromes (SM-AHN, MPN with eosinophilia): single disease biology or parallel processes? Andreas Reiter, Germany |
| 10:45-11:00 | Managing relapsed/refractory Hodgkin lymphoma: Checkpoint inhibitors, and beyond: Graham Collins, UK |
10:45-11:00 | Lessons learned from two decades of experience with KIT inhibitors in systemic mastocytosis: Jason Gotlib, USA |
| 11:00-11:15 | Panel discussion: All session faculty | 11:00-11:15 | Advanced systemic mastocytosis treatment in 2026: lessons for risk-adapted therapy in MPNs: Deepti Radia, UK |
| 11:15-12:30 | Industry Symposium | 11:15-12:30 | Industry Symposium |
| 12:30-13:00 | Lunch Break | ||
| 13:00-14:15 | COLYM 5: Rare, Neglected, and Difficult Lymphomas | 13:00-14:15 | MPNCo&D 5: New options for Essential Thrombocythemia and Polycythemia Vera — are they needed and when should we use them? |
| Moderators: Mohamed Kharfan-Dabaja, USA; TBA | Moderators: Lina Benajiba, France; Claire Woodley, UK | ||
| 13:00-13:05 | Case report: TBA | 13:00-13:15 | Interferon — which patients with ET and PV should have it and what is the treatment target? Lina Benajiba, France |
| 13:05-13:15 | Discussion | ||
| 13:15-13:30 | Peripheral T-cell lymphomas: are we finally improving outcomes? Eva Domingo-Domènech, Spain |
13:15-13:30 | Hepcidin mimetics — how will they be used for PV patients? Naveen Pemmaraju, USA |
| 13:30-13:45 | Primary CNS and extranodal lymphomas: unmet needs and new strategies: Kate Cwynarski, UK |
13:30-13:45 | Emerging precision therapies in ET: Anna Godfrey, UK |
| 13:45-14:00 | Management of post-transplant lymphoproliferative disorders (PTLD) and immunodeficiency-associated lymphomas: TBA |
13:45-14:00 | MPN Symptom Burden / Navigating ET and PV from Patient and Caregiver Perspective: Clinical Pearls from the Frontlines: Claire Woodley, UK |
| 14:00-14:15 | Panel discussion: All session faculty | 14:00-14:15 | Panel discussion: All session faculty |
| 14:15-15:30 | IACH 4 | ||
| 15:30-15:45 | Coffee Break | ||
| 15:45-16:15 | IACH 5 | ||
| Thursday, October 15th | |
|---|---|
| Hall A | Hall B |
| 08:45–09:00 Welcome Coffee |
|
| 09:00–12:00 IACH 1: Workshop |
|
| 12:00–12:30 Lunch Break |
|
| 12:30–13:00 IACH 2: Awards Session |
|
| 13:00–14:15 Transplant 1 |
13:00–14:15 COMydAL 1: MDS I Moderators: TBA |
| 13:00–13:15A new MDS classification ahead? TBA | |
| 13:15–13:30AI in diagnosis and prognostication of MDS and CMML: TBA | |
| 13:30–13:45Is there a border between AA and hMDS? TBA | |
| 13:45–14:00Germline predisposition in MDS, diagnosis and impact on therapy: TBA | |
| 14:00–14:15Panel discussion: All session faculty | |
| 14:15–15:30 Transplant 2 |
14:15–15:30 COMydAL 2: MDS II Moderators: Valeria Santini (Italy); TBA |
| 14:15–14:30Transplant for MDS in 2026? TBA | |
| 14:30–14:45Diagnosis and treatment of VEXAS and MDS: TBA | |
| 14:45–15:00Therapy of HR MDS: are target drugs the only hope? TBA | |
| 15:00–15:15Navigating the treatment of LR-MDS: TBA | |
| 15:15–15:30Panel discussion: All session faculty | |
| 15:30–16:45 Industry Symposium |
15:30–16:45 Industry Symposium |
| 16:45–17:00 Coffee Break |
|
| 17:00–18:15 Transplant 3 |
17:00–18:15 COMydAL 3: CMML, MDS/MPN and others Moderators: Valeria Santini (Italy); TBA |
| 17:00–17:15New directions in management of TP53 mutated myeloid neoplasms: Maximilian Stahl (USA) | |
| 17:15–17:30Evolving use of oral HMAs in myeloid malignancies: Daniel Wiseman (UK) | |
| 17:30–17:45Recommendation transplantation in CMML and MDS/MPN: TBA | |
| 17:45–18:00Biology and treatment of CMML: TBA | |
| 18:00–18:15Panel discussion: All session faculty | |
| Friday, October 16th | |
|---|---|
| Hall A | Hall B |
| 08:30–09:45 Transplant 4 |
08:30–09:45 COMydAL 4: AML I Moderators: Tamara Vasilj (Croatia); Amer Zeidan (USA) |
| MyeloMatch and pivotal AML studies to watch for in the next 3 years: TBA | |
| An update on FLT3 inhibitors use in AML: TBA | |
| An update on IDH inhibitors use in AML: Stéphane De Botton (France) | |
| An update on menin inhibitors use in AML: Amer Zeidan (USA) | |
| Panel discussion: All session faculty | |
| 09:45–10:00 Coffee Break |
|
| 10:00–11:15 Transplant 5 |
10:00–11:15 COMydAL 5: AML II Moderators: Sanam Loghavi (USA); Amer Zeidan (USA) |
| How should TP53 mutated myeloid neoplasms be classified? TBA | |
| Updates on clinical use of MRD for clinical management of AML: Christoph Röllig (Germany) | |
| Learnings from HARMONY about genetics determinants of outcomes in AML: TBA | |
| Harmonization efforts of classifications for AML and MDS: Sanam Loghavi (USA) | |
| Panel discussion: All session faculty | |
| 11:15–12:30 Industry Symposium |
11:15–12:30 Industry Symposium |
| 12:30–13:00 Lunch Break |
|
| 13:00–14:15 COLYM 1: From Biology to Bedside: What Will Really Change Practice? Moderators: TBA |
13:00–13:05 Opening: Claire Harrison (UK); Ruben Mesa (USA); Naveen Pemmaraju (USA) |
| 13:05–14:15 MPNCo&D 1: Redefining disease and risk: are we stratifying patients correctly? Moderators: Florian Heidel (Germany); TBA |
|
| 13:00–13:05 Case report: TBA |
13:05–13:20 Patient perspective on MPN priorities for 2026 and beyond: Werner Zinkland (Germany) |
| 13:05–13:15 Discussion |
13:20–13:35 Molecular risk models vs clinical judgement: are mutations driving overtreatment? Should we use them more in ET and PV: Jean-Jacques Kiladjian (France) |
| 13:15–13:30 Molecular subtyping and functional genomics: what is ready for routine care? TBA |
13:35–13:50 Clonal hematopoiesis vs early MPN: when does ‘watch and wait’ become unsafe? TBA |
| 13:30–13:45 ctDNA as a decision-making tool: hype, hope, or hard evidence? Sven Borchmann (Germany) |
13:50–14:05 Symptoms, spleen, survival: which outcome should drive first-line therapy choices in MF? Claire Harrison (UK) |
| 13:45–14:00 Emerging biomarkers for response prediction to novel agents: Brian Hill (USA) |
14:05–14:15 Panel discussion: All session faculty |
| 14:00–14:15 Panel discussion: All session faculty |
|
| 14:15–15:30 Industry Symposium |
14:15–15:30 Industry Symposium |
| 15:30–16:45 COLYM 2: Redefining Frontline Therapy: Risk, Response, and Reality Moderators: TBA |
15:30–16:45 MPNCo&D 2: Anemia in myelofibrosis: mechanism-driven therapy or trial-and-error? Moderators: David Ross (Australia); TBA |
| 15:30–15:35 Case report: TBA |
15:30–15:45 What causes anemia in MF — cytokines, hepcidin, marrow failure, or treatment effect? David Ross (Australia) |
| 15:35–15:45 Discussion |
15:45–16:00 ESAs, danazol, steroids: obsolete, underused, or still foundational? Susanne Isfort (Germany) |
| 15:45–16:00 Biology-driven frontline strategies in aggressive B-cell lymphomas: Andrew Davies (UK) |
16:00–16:15 Novel agents targeting anemia pathways in MF: Searching for the Holy Grail: Ruben Mesa (USA) |
| 16:00–16:15 Frontline therapy in high-risk subgroups: elderly fit patients with LBCL: Farrukh Awan (USA) |
16:15–16:35 Anemia as a prognostic marker vs a treatment-limiting toxicity: should it dictate therapy choice? Yes: Juan Carlos Hernandes-Boluda (Spain) No: TBA |
| 16:15–16:30 Managing primary refractory and early relapsed aggressive B-cell lymphomas: optimizing salvage and bridging strategies: TBA |
16:35–16:45 Panel discussion: All session faculty |
| 16:30–16:45 Panel discussion: All session faculty |
|
| 16:45–17:00 Coffee Break |
|
| 17:00–18:15 IACH 3 |
|
| Saturday, October 17th | |
|---|---|
| Hall A | Hall B |
| 08:30–09:45 COLYM 3: Sequencing in Relapsed Lymphoma: Making Sense of Too Many Options Moderators: TBA | 08:30–09:45 MPNCo&D 3: Next-generation targeted therapies: beyond JAK inhibition in MF Moderators: Susanne Isfort (Germany); Andreas Reiter (Germany) |
| 08:30–08:35 Case report: TBA | 08:30–08:45 Selective pathway targeting (e.g. hepcidin, ACVR1, BCL-2 family, Xpo1, MDM2): real differentiation or incremental gains? Jennifer O’Sullivan (UK) |
| 08:35–08:45 Discussion | |
| 08:45–09:00 Bispecific antibodies vs cellular therapies in FL: how to choose in real-life practice: TBA | 08:45–09:00 Early signals from novel agents targeting CALR in MF: how should clinicians interpret phase 1-2 data? Bethan Psaila (UK) |
| 09:00–09:15 Treatment sequencing in relapsed / refractory MZL: what do we do next? TBA | 09:00–09:15 Early data on novel JAK inhibitors: molecular markers, phenotype, or treatment history? John Mascarenhas (USA) |
| 09:15–09:30 Treatment sequencing in relapsed / refractory MCL: what do we do next? Carlo Visco (Italy) | 09:15–09:35 Combination strategies for upfront management: all patients INT-1 or above with splenomegaly and symptoms should receive combination therapy if trials are positive Yes: Francesco Passamonti (Italy) No: Florian Heidel (Germany) |
| 09:30–09:45 Panel discussion: All session faculty | 09:35–09:45 Panel discussion: All session faculty |
| 09:45–10:00 Coffee Break | |
| 10:00–11:15 COLYM 4: Hodgkin Lymphoma: Optimizing Therapy Across Risk Groups Moderators: TBA | 10:00–11:15 MPNCo&D 4: Transplant, disease evolution, and overlap biology Moderators: Anna Godfrey (UK); Juan Carlos Hernandes-Boluda (Spain) |
| 10:00–10:05 Case report: TBA | 10:00–10:15 Who should be referred for transplant today — and who is being missed? TBA |
| 10:05–10:15 Discussion | |
| 10:15–10:30 Frontline therapy in advanced-stage classical Hodgkin lymphoma: balancing efficacy and toxicity: TBA | 10:15–10:30 Timing allo-HSCT for atypical MPN: earlier, later, or never? Nicola Polverelli (Italy) |
| 10:30–10:45 PET-adapted and response-adapted strategies: how low can we go? TBA | 10:30–10:45 Overlap syndromes (SM-AHN, MPN with eosinophilia): single disease biology or parallel processes? Andreas Reiter (Germany) |
| 10:45–11:00 Managing relapsed / refractory Hodgkin lymphoma: Checkpoint inhibitors, and beyond: Graham Collins (UK) | 10:45–11:00 Lessons learned from two decades of experience with KIT inhibitors in systemic mastocytosis: Jason Gotlib (USA) |
| 11:00–11:15 Panel discussion: All session faculty | 11:00–11:15 Advanced systemic mastocytosis treatment in 2026: lessons for risk-adapted therapy in MPNs: Deepti Radia (UK) |
| 11:15–12:30 Industry Symposium | 11:15–12:30 Industry Symposium |
| 12:30–13:00 Lunch Break | |
| 13:00–14:15 COLYM 5: Rare, Neglected, and Difficult Lymphomas Moderators: TBA | 13:00–14:15 MPNCo&D 5: New options for ET and PV — are they needed and when should we use them? Moderators: Claire Woodley (UK); TBA |
| 13:00–13:05 Case report: TBA | 13:00–13:15 Interferon — which patients with ET and PV should have it and what is the treatment target? Lina Benajiba (France) |
| 13:05–13:15 Discussion | |
| 13:15–13:30 Peripheral T-cell lymphomas: are we finally improving outcomes? Eva Domingo-Domènech (Spain) | 13:15–13:30 Hepcidin mimetics — how will they be used for PV patients? Naveen Pemmaraju (USA) |
| 13:30–13:45 Primary CNS and extranodal lymphomas: unmet needs and new strategies: TBA | 13:30–13:45 Emerging precision therapies in ET: Anna Godfrey (UK) |
| 13:45–14:00 Management of PTLD and immuno deficiency-associated lymphomas: TBA | 13:45–14:00 MPN Symptom Burden / Navigating ET and PV from Patient and Caregiver Perspective: Clinical Pearls from the Frontlines: Claire Woodley (UK) |
| 14:00–14:15 Panel discussion: All session faculty | 14:00–14:15 Panel discussion: All session faculty |
| 14:15–15:30 IACH 4 | |
| 15:30–15:45 Coffee Break | |
| 15:45–16:15 IACH 5 | |